Aimee Luat
Neurology with Special Qualifications in Child Neurology · Detroit, MINPI 1326216821
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.9%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Neuropace, Inc. at 29.2% of the total. Reporting peaked in 2019 at $3,965 and has fallen 82.7% since, to $684 in 2025.
Across 104 payments — averaging $112.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$3K
- Biocodex, Inc.$2K
- Eisai Inc.$2K
- UCB, Inc.$872
- Neurelis, Inc.$784
- Jazz Pharmaceuticals Inc.$461
- plus $2K from 16 others
Across 45 payments — averaging $2434.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Immedica Pharma US, Inc.$44K
- Eisai Inc.$31K
- Zogenix Inc.$20K
- UCB SA$15K
What the payments were for
- Consulting fees$1,89516%
- Travel & lodging$3,35729%
- Food & beverage$6,42955%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 16 | $3,422 |
| Biocodex, Inc. | 4 | $2,390 |
| Eisai Inc. | 18 | $1,771 |
| UCB, Inc. | 17 | $872 |
| Neurelis, Inc. | 11 | $784 |
| Jazz Pharmaceuticals Inc. | 9 | $461 |
| Aquestive Therapeutics, Inc. | 6 | $303 |
| SK Life Science, Inc. | 2 | $249 |
| Livanova USA, Inc. | 3 | $211 |
| Mallinckrodt Enterprises LLC | 2 | $210 |
| Biomarin Pharmaceutical Inc. | 2 | $183 |
| Novartis | 1 | $133 |
| Greenwich Biosciences, Inc. | 2 | $129 |
| PTC Therapeutics, Inc. | 1 | $128 |
| Sunovion Pharmaceuticals Inc. | 1 | $122 |
| Zogenix Inc. | 2 | $85 |
| Sanofi | 2 | $84 |
| Pyros Pharmaceuticals, Inc. | 1 | $70 |
| Immedica Pharma US, Inc. | 1 | $30 |
| Biogen | 1 | $26 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DIACOMIT$2,365
- RNS System$1,793
- RNS Neurostimulator Kit$1,408
- Fycompa$1,302
- VALTOCO$466
- XCOPRI$249
- Epidiolex$247
- ACTHAR$210
- KESIMPTA$133
- LIBERVANT$133
- VNS Therapy$133
- Nayzilam$125
- Fintepla$125
- APTIOM$122
- SYMPAZAN$110
How this compares
$11,708 in reported general payments places this provider in the 85th percentile of 62 neurology with special qualifications in child neurology providers in Michigan.
See all neurology with special qualifications in child neurology providers in Michigan →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 31 | $133,995 |
| VimpatLacosamide | 19 | $26,753 |
| FycompaPerampanel | 13 | $13,498 |
| Clobazam | 30 | $2,469 |
| Lacosamide | 26 | $1,852 |
| Levetiracetam | 17 | $884 |
| Phenytoin | 14 | $267 |
| Phenobarbital | 17 | $238 |
| Clonazepam | 18 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Vimpat | $872 | $26,75319 claims |
| Eisai Inc.Fycompa | $1,771 | $13,49813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 62 neurology with special qualifications in child neurology providers in Michigan.
Other neurology with special qualifications in child neurology in Detroit
- Gyula AcsadiDetroit$86K
- Michelle FigueroaDetroit$57K
- Eishi AsanoDetroit$5K
- Jayaprakash GosalakkalDetroit$3K
- Daniela TaposDetroit$3K
- Beata RuprechtDetroit$2K
- Carla WatsonDetroit$1K
- Naznin MahmoodDetroit$972
- Fatema SerajeeDetroit$910
- Amanda WeberDetroit$772
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.